**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 4)1

Repare Therapeutics Inc.



(Name of Issuer)

Common Shares, no par value



(Title of Class of Securities)

760273102



(CUSIP Number)

June 2, 2022



(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* Rule 13d-1(b)
* Rule 13d-1(c)
* Rule 13d-1(d)



* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).



CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | Biotechnology Value Fund, L.P. |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 4,368,757 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 4,368,757 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 4,368,757 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 10.4% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | PN |  |  |
|  |  |  |  |  |
|  |  |  | 2 |  |

CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF I GP LLC |  |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 4,368,757 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 4,368,757 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 4,368,757 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 10.4% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | OO |  |  |
|  |  |  |  |  |
|  |  |  | 3 |  |

CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | Biotechnology Value Fund II, L.P. |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 3,231,579 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 3,231,579 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 3,231,579 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 7.7% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | PN |  |  |
|  |  |  |  |  |
|  |  |  | 4 |  |

CUSIP No. 760273102

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF II GP LLC |  |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  |  | (b) ☐ |
|  |  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 |  | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |  |
|  | BENEFICIALLY |  |  | 0 |  |
|  | OWNED BY | 6 |  | SHARED VOTING POWER |  |
|  | EACH |  |  |  |  |
|  | REPORTING |  |  | 3,231,579 |  |
|  | PERSON WITH | 7 |  | SOLE DISPOSITIVE POWER |  |
|  |  |  |  | 0 |  |
|  |  | 8 |  | SHARED DISPOSITIVE POWER |  |
|  |  |  |  | 3,231,579 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 3,231,579 |  |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 7.7% |  |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | OO |  |  |
|  |  |  |  |  |  |
|  |  |  |  | 5 |  |

CUSIP No. 760273102



|  |  |  |
| --- | --- | --- |
| 1 | NAME OF REPORTING PERSON |  |
|  | Biotechnology Value Trading Fund OS LP |  |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
| 3 | SEC USE ONLY |  |  |
|  |  |  |  |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  | Cayman Islands |  |  |
| NUMBER OF | 5 |  | SOLE VOTING POWER |  |
| SHARES |  |  |  |  |
| BENEFICIALLY |  |  | 0 |  |
| OWNED BY | 6 |  | SHARED VOTING POWER |  |
| EACH |  |  |  |  |
| REPORTING |  |  | 406,436 |  |
| PERSON WITH | 7 |  | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  | 8 |  | SHARED DISPOSITIVE POWER |  |
|  |  |  | 406,436 |  |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  | 406,436 |  |  |  |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |



Less than 1%



1. TYPE OF REPORTING PERSON PN



6



CUSIP No. 760273102

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF Partners OS Ltd. |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  |  | (b) ☐ |
|  |  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Cayman Islands |  |  |
|  | NUMBER OF | 5 |  | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |  |
|  | BENEFICIALLY |  |  | 0 |  |
|  | OWNED BY | 6 |  | SHARED VOTING POWER |  |
|  | EACH |  |  |  |  |
|  | REPORTING |  |  | 406,436 |  |
|  | PERSON WITH | 7 |  | SOLE DISPOSITIVE POWER |  |
|  |  |  |  | 0 |  |
|  |  | 8 |  | SHARED DISPOSITIVE POWER |  |
|  |  |  |  | 406,436 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 406,436 |  |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | Less than 1% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | CO |  |  |
|  |  |  |  |  |  |
|  |  |  |  | 7 |  |

CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF GP Holdings LLC |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 7,600,336 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 7,600,336 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 7,600,336 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 18.1% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | OO |  |  |
|  |  |  |  |  |
|  |  |  | 8 |  |

CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF Partners L.P. |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 8,141,988 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 8,141,988 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 8,141,988 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 19.4% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | PN, IA |  |  |
|  |  |  |  |  |
|  |  |  | 9 |  |

CUSIP No. 760273102

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  | 1 | NAME OF REPORTING PERSON |  |
|  |  | BVF Inc. |  |  |
|  | 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  |  |  | (b) ☐ |
|  |  |  |  |  |
|  | 3 | SEC USE ONLY |  |  |
|  |  |  |  |  |
|  | 4 | CITIZENSHIP OR PLACE OF ORGANIZATION |  |
|  |  | Delaware |  |  |
|  | NUMBER OF | 5 | SOLE VOTING POWER |  |
|  | SHARES |  |  |  |
|  | BENEFICIALLY |  | 0 |  |
|  | OWNED BY | 6 | SHARED VOTING POWER |  |
|  | EACH |  |  |  |
|  | REPORTING |  | 8,141,988 |  |
|  | PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  |  | 0 |  |
|  |  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  |  | 8,141,988 |  |
|  | 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  |  | 8,141,988 |  |  |
|  | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |  |
|  | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |
|  |  | 19.4% |  |  |
|  | 12 | TYPE OF REPORTING PERSON |  |
|  |  | CO |  |  |
|  |  |  |  |  |
|  |  |  | 10 |  |

CUSIP No. 760273102



* NAME OF REPORTING PERSON



|  |  |  |
| --- | --- | --- |
|  | Mark N. Lampert |  |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☒ |
|  |  | (b) ☐ |

* SEC USE ONLY



* CITIZENSHIP OR PLACE OF ORGANIZATION



|  |  |  |  |
| --- | --- | --- | --- |
|  | United States |  |  |
| NUMBER OF | 5 | SOLE VOTING POWER |  |
| SHARES |  |  |  |
| BENEFICIALLY |  | 0 |  |
| OWNED BY | 6 | SHARED VOTING POWER |  |
| EACH |  |  |  |
| REPORTING |  | 8,141,988 |  |
| PERSON WITH | 7 | SOLE DISPOSITIVE POWER |  |
|  |  | 0 |  |
|  | 8 | SHARED DISPOSITIVE POWER |  |
|  |  | 8,141,988 |  |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |  |
|  | 8,141,988 |  |  |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐ |
|  |  |  |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |  |

19.4%



1. TYPE OF REPORTING PERSON IN



11



CUSIP No. 760273102

|  |  |
| --- | --- |
| Item 1(a). | Name of Issuer: |
|  | Repare Therapeutics Inc., a Canada corporation (the “Issuer”). |
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
|  | 7210 Frederick-Banting, Suite 100 |
|  | St-Laurent, Québec, Canada H4S 2A1 |
| Item 2(a). | Name of Person Filing |
| Item 2(b). | Address of Principal Business Office or, if None, Residence |
| Item 2(c). | Citizenship |
|  | Biotechnology Value Fund, L.P. (“BVF”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | BVF I GP LLC (“BVF GP”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | Biotechnology Value Fund II, L.P. (“BVF2”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | BVF II GP LLC (“BVF2 GP”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | Biotechnology Value Trading Fund OS LP (“Trading Fund OS”) |
|  | PO Box 309 Ugland House |
|  | Grand Cayman, KY1-1104 |
|  | Cayman Islands |
|  | Citizenship: Cayman Islands |
|  | BVF Partners OS Ltd. (“Partners OS”) |
|  | PO Box 309 Ugland House |
|  | Grand Cayman, KY1-1104 |
|  | Cayman Islands |
|  | Citizenship: Cayman Islands |
|  | BVF GP Holdings LLC (“BVF GPH”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | BVF Partners L.P. (“Partners”) |
|  | 44 Montgomery St., 40th Floor |
|  | San Francisco, California 94104 |
|  | Citizenship: Delaware |
|  | 12 |

CUSIP No. 760273102

BVF Inc.

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

Item 2(d). Title of Class of Securities:

|  |  |
| --- | --- |
|  | Common Shares, no par value (the “Shares”). |
| Item 2(e). | CUSIP Number: |  |
|  | 760273102 |  |  |
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
|  |  | /x/ | Not applicable. |
|  | (a) | / / | Broker or dealer registered under Section 15 of the Exchange Act. |
|  | (b) | / / | Bank as defined in Section 3(a)(6) of the Exchange Act. |
|  | (c) | / / | Insurance company as defined in Section 3(a)(19) of the Exchange Act. |
|  | (d) | / / | Investment company registered under Section 8 of the Investment Company Act. |
|  | (e) | / / | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). |
|  | (f) | / / | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). |
|  | (g) | / / | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). |
|  | (h) | / / | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. |
|  | (i) | / / | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the |
|  |  |  | Investment Company Act. |
|  | (j) | / / | Group, in accordance with Rule 13d-1(b)(1)(ii)(J). |
|  | (k) | / / | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with |
|  |  |  | Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_ |
|  |  |  | 13 |

CUSIP No. 760273102

Item 4. Ownership

1. Amount beneficially owned:

As of the close of business on June 6, 2022, (i) BVF beneficially owned 4,368,757 Shares, (ii) BVF2 beneficially owned 3,231,579 Shares and (iii) Trading Fund OS beneficially owned 406,436 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,368,757 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,231,579 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 406,436 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 7,600,336 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 8,141,988 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the “Partners Managed Account”), including 135,216 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,141,988 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 8,141,988 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

1. Percent of class:

The following percentages are based on 41,894,235 Shares outstanding as of May 5, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2022.

14



CUSIP No. 760273102

As of the close of business on June 6, 2022, (i) BVF beneficially owned approximately 10.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 7.7% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 10.4% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 7.7% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 18.1% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 19.4% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

1. Number of shares as to which such person has:
2. Sole power to vote or to direct the vote See Cover Pages Items 5-9.
3. Shared power to vote or to direct the vote See Cover Pages Items 5-9.
4. Sole power to dispose or to direct the disposition of See Cover Pages Items 5-9.
5. Shared power to dispose or to direct the disposition of See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc., and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on June 29, 2020.

15



CUSIP No. 760273102

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

16



CUSIP No. 760273102

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 6, 2022

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert



Mark N. Lampert

Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert



Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert



Mark N. Lampert

Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert



Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert



Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert



Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert



Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert



Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert



President

/s/ Mark N. Lampert



MARK N. LAMPERT

17

